Cargando…
Hematological Alterations after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have benefits for survival in some cancers with peritoneal metastasis. Hematologic toxicity described rate is 2 to 38%. Methods: Patients admitted to an intensive care unit (ICU) after CRS and HIPEC over 78...
Autores principales: | Pintado, Maria Consuelo, Lasa Unzúe, Inmaculada, Gómez Sanz, Remedios, Diez Alonso, Manuel, Ortega, Miguel A., Álvarez de Mon, Melchor, Nevado Losada, Emilio, Gutierrez Calvo, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342859/ https://www.ncbi.nlm.nih.gov/pubmed/37445361 http://dx.doi.org/10.3390/jcm12134323 |
Ejemplares similares
-
Hyperthermic Intraperitoneal Chemotherapy and Recirculation with CO(2): A Safe Technique
por: Gómez-Sanz, Remedios, et al.
Publicado: (2022) -
Cytoreduction with hyperthermic intraperitoneal chemotherapy: An anaesthetic challenge
por: Murughan, Kavita, et al.
Publicado: (2014) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
por: Gamboa, Adriana C., et al.
Publicado: (2019) -
Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan
por: Hsieh, Mao-Chih, et al.
Publicado: (2017) -
Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?
por: Leigh, Natasha, et al.
Publicado: (2020)